Table 2 Human sample information

From: LRRK2-mutant microglia and neuromelanin synergize to drive dopaminergic neurodegeneration in an iPSC-based Parkinson’s disease model

Case

Gender

Age at death (years)

Disease duration (years)

PMI (hr)

Braak PD staging

Control-1

Female

59

N/A

2

N/A

Control-2

Male

59

N/A

6

N/A

Control-3

Male

59

N/A

5

N/A

Control-4

Male

60

N/A

N/A

N/A

Control-5

Female

60

N/A

N/A

N/A

Control-6

Female

61

N/A

N/A

N/A

Control-7

Female

62

N/A

2

N/A

Control-8

Male

63

N/A

N/A

N/A

Control-9

Male

63

N/A

12

N/A

Control-10

Female

65

N/A

N/A

N/A

Control-11

Male

65

N/A

N/A

N/A

Control-12

Female

66

N/A

N/A

N/A

Control-13

Male

69

N/A

N/A

N/A

Control-14

Female

70

N/A

14

N/A

Control-15

Female

70

N/A

N/A

N/A

Control-16

Female

71

N/A

N/A

N/A

Control-17

Female

73

N/A

N/A

N/A

Control-18

Female

74

N/A

N/A

N/A

Control-19

Male

76

N/A

11.5

N/A

Control-20

Male

78

N/A

4

N/A

Control-21

Female

79

N/A

N/A

N/A

Control-22

Female

79

N/A

N/A

N/A

Control-23

Male

81

N/A

2

N/A

Control-24

Male

83

N/A

13

N/A

Control-25

Female

83

N/A

7.2

N/A

Control-26

Female

83

N/A

4

N/A

Control-27

Male

84

N/A

4

N/A

Control-28

Female

86

N/A

4

N/A

Control-29

Female

90

N/A

12.25

N/A

Control-30

Female

91

N/A

8

N/A

Control-31

Male

91

N/A

N/A

N/A

Control-32

Female

94

N/A

N/A

N/A

iPD-1

Male

76

N/A

N/A

iPD

iPD-2

Female

77

N/A

N/A

iPD

iPD-3

Male

77

N/A

N/A

iPD

iPD-4

Male

77

N/A

N/A

iPD

iPD-5

Male

80

N/A

N/A

iPD

iPD-6

Female

81

N/A

N/A

iPD

iPD-7

Male

81

N/A

N/A

iPD

iPD-8

Female

85

N/A

N/A

iPD

iPD-9

Female

88

N/A

N/A

iPD

L2-PD-1

Male

84

N/A

20

I-II

L2-PD-2

Female

78

26

27.5

IV

L2-PD-3

Female

77

10

8

N/A

L2-PD-4

Female

93

15

7

IV

L2-PD-5

Female

69

17

12.5

V

L2-PD-6

Male

69

N/A

15.5

N/A

  1. L2-PD LRRK2-PD, iPD Idiopathic PD, PMI post-mortem interval (hours), N/A not available.